Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Invested Capital (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Invested Capital for 7 consecutive years, with $192.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 56.1% year-over-year to $192.3 million, compared with a TTM value of $192.3 million through Sep 2025, down 56.1%, and an annual FY2024 reading of $388.7 million, up 400.37% over the prior year.
  • Invested Capital was $192.3 million for Q3 2025 at Summit Therapeutics, down from $259.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $437.9 million in Q3 2024 and bottomed at $44.2 million in Q1 2024.
  • Average Invested Capital over 5 years is $159.9 million, with a median of $119.6 million recorded in 2023.
  • The sharpest move saw Invested Capital crashed 66.88% in 2024, then surged 678.85% in 2025.
  • Year by year, Invested Capital stood at $83.3 million in 2021, then skyrocketed by 52.07% to $126.7 million in 2022, then plummeted by 38.66% to $77.7 million in 2023, then soared by 400.37% to $388.7 million in 2024, then crashed by 50.54% to $192.3 million in 2025.
  • Business Quant data shows Invested Capital for SMMT at $192.3 million in Q3 2025, $259.4 million in Q2 2025, and $344.3 million in Q1 2025.